Inhaled nitric oxide in the treatment of hypoxemic respiratory failure

Current Opinion in Pediatrics

Volumn 10, Issue 3, 1998, Pages 284-290

  Kass, Lewis J ^b   Apkon, Michael ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

ARTERY DILATATION; BLOOD OXYGENATION; CLINICAL TRIAL; EXTRACORPOREAL OXYGENATION; GAS EXCHANGE; HUMAN; HYPOXEMIA; HYPOXIC LUNG VASOCONSTRICTION; INHALATIONAL DRUG ADMINISTRATION; LUNG VENTILATION PERFUSION RATIO; NEWBORN; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; WITHDRAWAL REFLEX;

ADMINISTRATION, INHALATION; ASPHYXIA NEONATORUM; CHILD; CRITICAL CARE; HUMANS; INFANT, NEWBORN; NITRIC OXIDE; PULMONARY GAS EXCHANGE; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY INSUFFICIENCY; VASODILATOR AGENTS;

EID: 0031704497     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199806000-00011     Document Type: Review

References (27)

1. Davis SL, Furman DP, Costarino AT Jr: Adult respiratory distress syndrome in children: Associated disease, clinical course, and predictors of death. J Pediatr 1993, 123:35-45.
2. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
3. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
4. Hopkins SR, Johnson EC, Richardson RS, Wagner H, De Rosa M, Wagner PD: Effects of inhaled nitric oxide on gas exchange in lungs with shunt or poorly ventilated areas. Am J Respir Crit Care Med 1997, 156:484-491. Reports the influence of iNO on the distribution of V/Q ratios throughout the lungs in experimental models of V/Q mismatch and shunt. These investigators used the multiple inert gas elimination technique to characterize the V/Q distribution and found that iNO may worsen oxygenation under some circumstances by relieving hypoxic pulmonary vasoconstriction.
5. Katayama Y, Higenbottam TW, Diaz de Atauri MJ, et al.: Inhaled nitric oxide and arterial oxygen tension in patients with chronic obstructive pulmonary disease and severe pulmonary hypertension. Thorax 1997, 52:120-124.
6. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R: Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996, 347:436-440.
7. Anonymous: Inhaled nitric oxide and hypoxic respiratory failure in Infants with congenital diaphragmatic hernia. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Pediatrics 1997, 99:838-845.
8. Barefield ES, Karle VA, Phillips JB 3rd, Carlo WA: Inhaled nitric oxide in term Infants with hypoxemic respiratory failure. J Pediatr 1996, 129:279-286.
9. Anonymous: Inhaled nitric oxide in full-term and nearly full-term Infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 1997, 336:597-604. Placebo-controlled, multicenter, randomized clinical trial of iNO in neonatal patients with hypoxemic respiratory failure demonstrating an improvement in outcome defined as a reduced risk of being treated with extracorporeal membrane oxygenation or dying. Included patients with and without evidence of pulmonary hypertension.
10. Roberts JD Jr, Fineman JR, Monn FC 3rd, et al.: Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997, 336:605-610. Multicenter, randomized clinical trial of iNO in neonatal patients with hypoxemic respiratory failure demonstrating an improvement in outcome defined as a reduced risk of being treated with extracorporeal membrane oxygenation. This study was limited to patients with evidence of pulmonary hypertension. No difference in mortality was noted between the iNO-treated and control groups.
11. Hoffman GM, Ross GA, Day SE, Rice TB, Nelin LD: Inhaled nitric oxide reduces the utilization of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn. Crit Care Med 1997, 25:352-359.
12. Kinsella JP, Truog WE, Walsh WF, et al.: Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997, 131:55-62.
13. Day RW, Guarin M, Lynch JM, Vernon DD, Dean JM: Inhaled nitric oxide In children with severe lung disease: Results of acute and prolonged therapy with two concentrations. Crit Care Med 1996, 24:215-221.
14. Demirakca S, Dotsch J, Knothe C, et al.: Inhaled nitric oxide in neonatal and pediatric acute respiratory distress syndrome: Dose response, prolonged inhalation, and weaning. Crit Care Med 1996, 24:1913-1919.
15. Buga GM, Griscavage JM, Rogers NE, Ignarro LJ: Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res 1993, 73:808-812.
16. Lavoie A, Hall JB, Olson DM, Wylam ME: Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med 1998, 153:1985-1987.
17. Atz AM, Adatia I, Wessel DL: Rebound pulmonary hypertension after Inhalation of nitric oxide. Ann Thorac Surg 1996, 62:1759-1764. This report describes the time course of rebound pulmonary hypertension after discontinuing iNO therapy. This report is helpful in defining expectations as therapy is weaned and provides important information that may be useful in avoiding unnecessarily prolonged therapy.
18. Hallman M, Bry K, Lappalainen U: A mechanism of nitric oxide-induced surfactant dysfunction. J Appl Physiol 1996, 80:2035-2043.
19. Hallman M, Waffarn F, Bry K, et al.: Surfactant dysfunction after inhalation of nitric oxide. J Appl Physiol 1996, 80:2026-2034.
20. Hallman M, Turbow R, Waffarn F, et al.: Surfactant dysfunction after inhalation of nitric oxide (NO): Additive effects of hypoxia. Pediatr Res 1994, 35:336A.
21. Hallman M, Maasilta P, Kivisaari L, Mattson K: Changes in surfactant in bronchoalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma. Am Rev Respir Dis 1990, 141:998-1005.
22. Radomski MW, Palmer RM, Moncada S: The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987, 148:1482-1489.
23. Radomski MW, Palmer RM, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987, 2:1057-1058.
24. Hogman M, Frostell C, Arnberg H, Sandhagen B, Hedenstierna G: Prolonged bleeding time during nitric oxide Inhalation in the rabbit Acts Physiol Scand 1994, 151:125-129.
25. Gries A, Bottiger BW, Dorsam J, et al.: Inhaled nitric oxide inhibits platelet aggregation after pulmonary embolism in pigs. Anesthesiology 1997, 86:387-393.
26. Albert J, Wallen NH, Broijersen A, Frostell C, Hjemdahl P: Effects of inhaled nitric oxide compared with aspirin on platelet function in vivo in healthy subjects. Clin Sci 1996, 91:225-231.
27. Day RW, Lynch JM, White KS, Ward RM: Acute response to Inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics 1996, 98:698-705.